Background: Docetaxel has yielded promising response rates as a component of doxorubicin-based combination schedules in patients with metastatic breast cancer, including docetaxel/doxorubicin and docetaxel/doxorubicin/cyclophosphamide (AC). This randomized two-stage phase II study was conducted to evaluate sequential treatment with docetaxel and AC as first-line treatment in patients with recurrent or metastatic breast cancer previously untreated with chemotherapy for metastatic disease.
Introduction
Breast cancer is still a leading cause of cancer death in women in the United States and Europe [1, 2] . Randomized clinical trials have demonstrated that the extent of surgical resection is not the sole determinant of clinical outcome [3] , and that systemic therapy following surgery improves both diseasefree survival and overall survival [4] . However, a recent metaanalysis of adjuvant chemotherapy trials for patients with breast cancer showed that ∼40% of patients experience recurrence [5] . Among current polychemotherapies used in the adjuvant setting, anthracycline-containing schedules have a modest but real impact on breast cancer survival rates.
Although many chemotherapeutic modalities have been investigated to optimize antitumor efficacy in patients with metastatic breast cancer, how best to integrate different modalities remains an important clinical question. Specifically, it has not been resolved whether patients should receive effective agents sequentially in response to tumor progression (use one and reserve others until after tumor progression to the first therapy), or whether clinical activity can be improved by alternating or sequencing chemotherapy agents before tumor progression. An anthracycline, doxorubicin, has been shown to be an active agent in the first-and second-line treatment of advanced breast cancer. Doxorubicin as a single agent demonstrated overall response rates of 29-41% in phase II and III trials of patients with metastatic breast cancer [6] . Combination chemotherapy with doxorubicin/cyclophosphamide (AC) produced response rates of 45-65% in the metastatic setting [7] .
In the 1990s, docetaxel, a semi-synthetic compound derived from the needles of the yew tree Taxus bacata, emerged as an active new agent in the treatment of breast cancer [8] . Overall response rates of up to 68% were achieved in phase II trials of docetaxel at a dose of 100 mg/m 2 as a first-line treatment for metastatic disease [9] [10] [11] [12] . Randomized phase III trials in patients treated previously with anthracycline-containing schedules showed a significant increase in both the response rate and median time to progression with docetaxel over nontaxane, non-anthracycline combination schedules [13] [14] [15] . Notably, second-line treatment with docetaxel has yielded significant antitumor activity in patients with strictly defined anthracycline-resistant metastatic breast cancer, thus suggesting a relative lack of complete cross-resistance between the drugs [16, 17] .
Given the well-established role of doxorubicin and the high activity of docetaxel in the treatment of metastatic breast cancer, it seemed logical to study the two drugs in combination [18] [19] [20] [21] [22] [23] . The differences in activity and mechanisms of action between AC combination chemotherapy and the single agent docetaxel made these modalities an attractive set of therapies to study in combination.
Deregulation of cell growth by the ErbB family of receptor tyrosine kinases is most often associated with breast cancer [24, 25] . This family of receptors comprises four structurally related transmembrane receptors: the epidermal growth factor receptors (EGFR, ErbB1, HER1), ErbB2 (HER2, neu), ErbB3 (HER3) and ErbB4 (HER4) [26] . Amplification and overexpression of the c-erbB1 and c-erbB2 proto-oncogenes and their protein products have been found in breast carcinomas, and have been associated with disease recurrence and poorer prognosis [27] [28] [29] [30] [31] [32] [33] . In addition to the transmembrane forms of ErbB receptors, secreted or soluble isoforms (sErbB), which contain only the extracellular domain (ECD), are produced by normal and malignant cells [34] . These soluble isoforms of ErbB receptors are currently being examined as possible cancer biomarkers [35] [36] . Immunoassays have shown that sErbB1 concentrations are decreased in the urine of patients with bladder cancer and in the serum of females with advanced-stage epithelial ovarian cancer [37] [38] [39] . In contrast, serum sErbB2 concentrations are elevated in women with breast and ovarian cancer in comparison with healthy women [40] [41] [42] [43] [44] [45] [46] [47] . In addition, elevated pre-treatment sErbB2 concentrations have been correlated with poor clinical responsiveness to hormone therapy and chemotherapy in metastatic breast cancer patients [48] [49] [50] [51] . Together, these studies suggest that alterations in serum sErbB concentrations may be useful in diagnosing cancer, in monitoring disease recurrence, and in predicting therapeutic responsiveness and disease outcome in cancer patients.
Against this background, we conducted a randomized study to assess the antitumor activity and toxicity profiles of two sequential schedules of docetaxel and AC in women with recurrent or metastatic breast cancer. We also compared pretreatment serum sErbB1 and sErbB2 protein concentrations with those of an age-and menopausal status-matched group of healthy women, and examined changes in serum sErbB1 and sErbB2 protein concentrations in these two treatment schedules.
Patients and methods

Patients
This was a randomized, multicenter study conducted by the North Central Cancer Treatment Group between October 1997 and June 1998, with the approval of the institutional review boards of each participating institution and the informed, written consent of all participants. The study population consisted of women (aged ≥18 years) with recurrent or metastatic breast cancer. The eligibility criteria were measurable or assessable disease, Eastern Cooperative Oncology Group performance status <2, life expectancy ≥6 months, adequate hematological values [absolute neutrophil count (ANC) ≥1500/µl and platelet count ≥100 000/µl] and adequate renal and hepatic function [creatinine ≤1.5 × the upper limit of normal (ULN), total bilirubin within normal limits and aspartate transaminases <2.5 ULN].
Patients were excluded if they had received prior systemic chemotherapy for metastatic breast cancer. Prior adjuvant anthracyclinecontaining adjuvant therapy was allowed only if the cumulative dose was <240 mg/m 2 and the patient had a normal cardiac ejection fraction. Prior radiation to >25% of the bone marrow was not permitted. Other exclusion criteria included prior malignancy (except adequately treated basal cell or squamous cell skin carcinoma, adequately treated non-invasive carcinoma, and other carcinomas from which the patient had been disease-free for ≥5 years), uncontrolled infection, congestive heart failure requiring medication, central nervous system metastases, pre-existing effusion, ascites or peripheral edema, and poorly controlled diabetes mellitus. Pregnant or lactating women were not eligible for this study.
Treatment plan
Drug treatment. Patients were randomized to two multicenter phase II trials (conducted independently of each other) examining two different schedules of docetaxel and AC ( Figure 1 Dose adjustments. Dose modifications were performed based on toxicity grading with the National Cancer Institute common toxicity criteria (NCI-CTC). The docetaxel dose was to be reduced by 20% if a patient developed grade 4 neutropenia or thrombocytopenia, grade 3 non-hematological toxicity, or grade 2 edema; a 25% reduction for 2.5 × ULN < aspartate aminotransferase (AST) ≤5 × ULN; a 30% dose reduction was recommended for grade 4 non-hematological toxicity; and treatment was to be discontinued for AST >5 × ULN, grade 3 or 4 edema or grade 4 reactions. The AC dose was to be reduced by 20% in patients with grade 4 neutropenia or thrombocytopenia or grade 3 non-hematological toxicity, and by 30% in patients with grade 4 non-hematological toxicity. Treatment was to be continued until disease progression or unacceptable toxicity occurred. After discontinuation of the study treatment, all patients were to be followed for long-term toxicity, progression and survival every 3 months for the first 2 years post-randomization and yearly thereafter.
Supportive care. Anti-emetic medication was given as clinically indicated. Granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor was not to be administered prophylactically or substituted for protocol-stipulated dose reductions due to toxicity, but therapeutic use was permitted in patients with serious neutropenic complications.
Treatment evaluation
The pre-treatment evaluation included a medical history, physical examination, chest X-ray, radiology evaluation of the indicator lesion [e.g. computed tomography (CT) scan, magnetic resonance imaging (MRI) scan], left ventricular ejection fraction in patients with a cumulative anthracycline dose ≥240 mg/m 2 , complete blood count (white blood cells, ANC, hemoglobin, platelets), biochemistry assessments (creatinine, alkaline phosphatase, total bilirubin, calcium, AST) and a serum pregnancy test for women of childbearing potential. During the study, complete blood counts were performed on days 7-10 of each cycle, every other day until ANC >500/ml when ANC ≤500/ml, and before each cycle. Physical examination and biochemical assessments were performed before each cycle; indicator lesions were evaluated after cycles 3 and 5, and in cases of response, after cycle 6. Toxicity was evaluated at baseline and before retreatment. A measurable indicator lesion was defined as a tumor mass with clearly defined unidimensional or bidimensional measurements, with a minimum size of its largest diameter of 1.0 cm as measured by physical examination or chest X-ray, or 2.0 cm as measured by CT scan, MRI scan or ultrasound. An assessable indicator lesion was defined as a radiologically visible tumor mass which could be assessed in terms of changes in size, but which could not be clearly measured in two dimensions. Complete response (CR) was defined as the total disappearance of all evidence of tumor. For measurable lesions, a partial response (PR) was defined as a ≥50% reduction in the sum of the products of the largest perpendicular diameters (bidimensional lesion), or a ≥30% reduction in the linear tumor measurement (unidimensional lesion). For an assessable lesion, a regression (REGR) was defined as a ≥50% decrease in tumor size. Progressive disease was defined as either: (i) the appearance of a new lesion; (ii) a significant clinical deterioration in the patient's condition that could not be attributed to treatment or other medical conditions; (iii) an increase of at least 25% of the decrease in size between pre-treatment measurements and the smallest measurements at the point of maximum tumor reduction for measurable indicator lesions that met the criteria for PR; (iv) a definite increase (≤25%) in tumor size compared with its smallest size while on study for assessable indicator lesions which met the criteria for REGR; or (v) at least a 25% increase in tumor size compared with pre-treatment size for those patients who did not meet the criteria for CR, PR or REGR. Patients who did not meet the criteria for CR, PR or REGR or progressive disease were considered to have stable disease.
Statistical analysis
The primary end point was the objective response rate after five cycles of treatment; this was defined as the proportion of eligible patients who achieved a CR, PR or REGR after cycle 5 that was maintained after cycle 6. The smallest objective response rate of interest for further study was 75%. The study was designed to test the null hypothesis that true response rate was at most 55% against the alternative that it was at least 75%. In the first stage, 15 eligible patients were randomized to each treatment schedule. If nine or fewer eligible patients on a given treatment schedule achieved a response after five cycles that was maintained after six cycles, then accrual to that treatment schedule would be terminated. The decision to terminate accrual to a particular treatment schedule was made independently of the antitumor activity of the other treatment schedule. If accrual were re-opened to one (both) of the treatment schedules, then 28 additional eligible patients would be accrued (randomized) to that (each) treatment schedule. If 29 or more of the 43 eligible patients accrued to a treatment schedule achieved a response after cycle 5 that was maintained after cycle 6, and excessive toxicity was not observed, then that treatment schedule would be recommended for further testing in subsequent clinical trials. For each treatment schedule, there was an 80% chance of detecting whether the objective response rate after five cycles of treatment was at least 75% at a significance level of 0.05.
Secondary end points were the response rate after three cycles of treatment, progression-free and overall survival, toxicity and dose intensity. The response rate after three cycles of treatment was defined as the percentage of eligible patients who achieve a CR, PR or REGR after the third cycle of treatment (not necessarily maintained at the end of a fourth cycle of treatment). Confidence intervals for the response rates were constructed using the properties of the binomial distribution. Progression-free survival was defined as the time from registration on study until documented disease progression. Patients who died without documentation of progression were considered to have progressive disease at the time of death. Overall survival time was defined as the time from registration on study until death due to any cause. The distributions of overall survival times and progression-free survival times were estimated using the Kaplan-Meier method. The delivered dose intensity was determined for each patient for whom the agents were administered. Dose intensity was defined as the dose of that agent/m 2 received during its first three cycles of administration divided by the number of weeks. For each level of toxicity, the proportion of patients who reported that toxicity (NCI-CTC grade 3 or higher) was determined.
Serum sErbB1 and sErbB2 immunoassays
Blood specimens were collected for serum sErbB1 and sErbB2 determinations at baseline, and before the fourth and seventh cycles of treatment. In addition, sErbB1 and sErbB2 serum concentrations were obtained from a cohort of age-and menopausal status-matched healthy women. These women were enrolled in a Mayo Foundation Institutional Review Board-approved Normal Values Study, which required each healthy donor to provide a recent medical history that included a physical examination and the results of hematological and chemistry groups, lipids, thyroid function, urinalysis, and chest X-rays and ECGs on ageappropriate subjects. All blood samples were processed and handled as described by Baron and co-workers [39] . Serum sErbB1 concentrations were determined using an acridiniumlinked immunosorbent assay (ALISA) specific for epitopes of the ErbB1 ECD [39] . Initially, all human sera were assayed in triplicate at dilutions of 1:10 in ALISA blocking buffer (ALBB). Serum samples yielding relative light units outside the linear range of the assay's standard curve were reassayed either undiluted or at a dilution of 1:20 in ALBB to obtain sErbB1 concentrations within the linear range of the standard curve.
Serum sErbB2 concentrations were determined using the sp185 HER-2 enzyme-linked immunosorbent assay (ELISA) (Bender MedSystems Diagnostics GmbH, Vienna, Austria) according to the manufacturer's instructions. All serum samples were initially tested in duplicate at a 1:20 dilution in assay buffer. Serum samples yielding absorbance units outside the linear range of the assay's standard curve were reassayed at either 1:5, 1:10 or 1:100 to obtain sErbB2 concentrations within the linear range of the standard curve.
Statistical analyses of serum sErbB concentrations
Pre-treatment sErbB1 and sErbB2 concentrations of all study patients were compared with a group of age-and menopausal status-matched healthy women using a Wilcoxon rank sum test. Changes in sErbB1 and sErbB2 concentrations were examined separately for each treatment schedule. Before the fourth and seventh cycle of treatment, the percentage changes in sErbB1 and sErbB2 from pre-treatment concentrations were determined, and the Wilcoxon signed rank test was used to determine if the median percentage change differed significantly from zero.
Results
Patient accrual
Thirty-four patients with previously untreated recurrent or metastatic breast cancer were randomized to receive docetaxel then AC or AC then docetaxel (each n = 17). One patient in the AC then docetaxel group was declared ineligible due to preexisting pleural effusion. The characteristics of the 33 eligible patients are presented in Table 1 . The two treatment groups were similar with respect to age, type of indicator lesion and number of metastatic sites. A suspension of accrual notice was sent out after 15 eligible patients were randomized to each treatment group, but three additional patients were allowed to start on trial as they had already begun eligibility evaluation. Accrual was terminated to each treatment group as fewer than 10 of the first 15 patients accrued into each group achieved an objective response.
Treatment course
The median number of cycles administered was seven (range 1-35) in the docetaxel then AC group, and 9.5 (range 1-23) in the AC then docetaxel group. Six patients (three from each treatment group) discontinued treatment after one cycle because of progression (three patients), death due to a myocardial infarction (MI) (one patient), refusal due to multiple toxicities including a reaction to the docetaxel infusion (one patient), and failure to rechallenge after a reaction to the docetaxel infusion (one patient). Twelve of the remaining 13 patients in the AC then docetaxel group had at least one dose reduction during the first six cycles of treatment. These dose reductions were because of severe neutropenia (nine patients), grade 4 vomiting and diarrhea (one), grade 4 stomatitis (one) and physician discretion (one). Twelve of the remaining 14 patients in the docetaxel then AC group had at lease one dose reduction during the first six cycles of treatment. These dose reductions were because of severe neutropenia (eight patients), anaphylactic reaction to docetaxel/not rechallenged (two), grade 3 neurosensory toxicity (one), poor venous access (one), and grade 2 edema (one). Table 2 . shows the dose intensity of each drug during the first six cycles of treatment.
Toxicity
Fifteen patients in the docetaxel then AC group and 16 in the AC then docetaxel group were evaluable for hematological toxicity. On docetaxel then AC, grade 4 neutropenia occurred in 12 patients (80%) during the first cycle and in 15 patients (100%) during the course of the study. On AC then docetaxel, grade 4 neutropenia occurred in 10 patients (63%) during the first cycle and 14 (88%) during the course of the study. Febrile neutropenia was observed in 6 of 15 patients (40%) on docetaxel then AC, and in 4 of 16 patients (25%) on AC then docetaxel (Table 3) .
Four patients, all in the docetaxel then AC group, had an allergic reaction to the docetaxel. Three of these patients were withdrawn from treatment because of the severity of the reaction without being rechallenged. The fourth patient refused to continue treatment having been rechallenged with i.v. premedication. Her dyspnea persisted and she experienced chills, arthralgia and myalgia. (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) In addition to the three patients who were withdrawn from treatment because of severe reactions to docetaxel, there were five patients who withdrew from treatment because of other severe non-hematological toxicities. These toxicities were: grade 4 cardiac dysrhythmia after 12 cycles of docetaxel then AC, grade 3 neurosensory and grade 2 neuromotor toxicities after 13 cycles on docetaxel then AC, febrile neutropenia and grade 4 vomiting after four cycles of AC then docetaxel, grade 4 edema and grade 3 dyspnea after nine cycles on AC then docetaxel, and grade 3 infected port resulting in treatment being delayed > 6 weeks after 10 cycles of AC then docetaxel.
Three patients experienced severe dyspnea, musculoskeletal pain, and thrombotic events in addition to the allergic reactions to docetaxel. All the remaining severe non-hematological toxicities observed occurred in no more than two patients.
Response
The primary efficacy end point was an objective response after five cycles of treatment that was maintained after the sixth cycle of treatment. There were one CR, four PRs and one REGR among the 17 patients in the docetaxel then AC group, and four PRs and two REGRs among the 16 patients in the AC then docetaxel group. Thus, the confirmed response rate after five cycles was 35% [95% confidence interval (CI) 14% to 62%] in the docetaxel then AC group and 38% (95% CI 15% to 65%) in the AC then docetaxel group. At the third cycle evaluation, there were one CR, three PRs and one REGR among the 17 patients in the docetaxel then AC group, and three PRs and two REGRs among the 16 patients in the AC then docetaxel group. Thus, the response rate after three cycles was 29% (95% CI 10% to 56%) in the docetaxel then AC and 25% (95% CI 11% to 59%) in the AC then docetaxel group. These data are presented in Table 4 .
Progression and survival
In the docetaxel then AC group, there is one patient alive who has not progressed, one patient who died at day 11 of an MI not having progressed, seven patients alive who progressed, and eight patients who progressed and died. In the AC then docetaxel group, there are three patients alive who have not progressed, three patients alive who progressed, and 10 patients who progressed and died. The median length of follow-up for those still alive is 2.5 years (range 2.1-3.0 years).
In the docetaxel then AC group, the median progressionfree survival time is 12 months and the median survival time is 2.5 years (Figure 2 ). In the AC to docetaxel group, the median progression-free survival time is 10.2 months and the median survival time is 1.1 years (Figure 3 ).
sErbB1 and sErbB-2 serum concentrations
Serum sErbB1 and sErbB2 concentrations were determined for 29 of the 33 eligible patients. Serum sErbB1 and sErbB2 Response proportion at cycle 3 evaluation 29% (95% CI 10% to 56%) 31% (95% CI 11% to 59%)
Response proportion at cycle 5 evaluation (ORR) 35% (95% CI 14% to 62%) 38% (95% CI 15% to 65%)
concentrations also were determined for a cohort of healthy women who were age-and menopausal status-matched to the clinical trial patients. The median pre-treatment sErbB1 level was 4700 fmol/ml (range 68-109954 fmol/ml) in the trial patients and 3156 fmol/ml (range 146-24 068 fmol/ml) in the healthy women (Figure 4 ). No significant difference was found between the pre-treatment sErbB1 concentrations of the study patients and those of the healthy women (P = 0.15). The median pre-treatment sErbB2 level was 7.05 ng/ml (range 1.24-433.38 ng/ml) in the trial patients and 2.08 ng/ml (range 0.90-19.72 ng/ml) in the healthy women ( Figure 5 ). The pre-treatment sErbB2 concentrations of the trial patients were significantly higher than those of the healthy women (P = 0.0003). Serum samples were available from 23 of the 25 patients who had three cycles of treatment (10 of 12 in the docetaxel then AC group; 13 of 13 in the AC then docetaxel group). Serum samples also were available from 15 of the 21 patients who received six cycles of treatment (8 of 10 in the docetaxel then AC group; seven of 11 in the AC then docetaxel group). The percentage change between pre-treatment sErbB1 concentrations and sErbB1 concentrations before the fourth or seventh treatment cycles was not significantly different from zero with either treatment schedule (all P values >0.35). In the docetaxel then AC group, the percentage change between pretreatment sErbB2 concentrations and sErbB2 concentrations before the fourth treatment cycle (after docetaxel) was not significantly different from zero (P = 0.432). Interestingly, the percentage change between the pre-treatment sErbB2 concentrations and sErbB2 concentrations before the seventh cycle (after AC) tended to be negative (P = 0.078). In the AC then docetaxel group, the percentage change between pre-treatment sErbB2 concentrations and sErbB2 concentrations before the fourth treatment cycle (after AC) was also negative (P = 0.021); however, the percentage change between pretreatment sErbB2 concentrations and sErbB2 concentrations before the seventh cycle (after docetaxel) did not differ from zero (P = 0.297).
Discussion
This randomized study was designed to investigate the efficacy and toxicity of two alternating, sequential schedules of docetaxel and AC. The population randomized to receive the two schedules was representative of patients with metastatic breast cancer commonly referred for treatment. Objective response rates of 35% and 38% were achieved after five cycles for docetaxel then AC and vice versa, respectively. These response rates were unexpectedly low, and, in accordance with the protocol, led to termination of the trial after the first stage of accrual.
The response rates observed in our study are similar to those achieved with doxorubicin alone in patients with metastatic breast cancer [6] . However, they were considerably lower than those obtained for docetaxel monotherapy in patients with metastatic disease [8, 17] .
Our response rates are also considerably lower than those obtained in studies of docetaxel-and doxorubicin-based combination therapy. For example, in a phase II randomized study, patients given doxorubicin/docetaxel had a 60% response rate, compared with 40% in patients given AC [22] . The three drug combination of docetaxel, doxorubicin and cyclophosphamide has yielded a response rate of 77% [23] . One of the potential explanations for our lower response rates may be that we defined response after five cycles of treatment, instead of the more commonly used two or three cycles of therapy.
Previous studies evaluating sequential schedules, including docetaxel and doxorubicin, yielded promising results. A response rate of 67% was reported for patients with metastatic breast cancer treated with docetaxel followed by doxorubicin [23] . Notably, a recent feasibility study conducted by Antoine et al. [52] of sequential docetaxel then AC as first-line treatment in patients with metastatic disease yielded a response rate of 71%, a median response duration of 53 weeks, a median time to progress of 46 weeks, and a median survival time of 25 months. Of note is that the median survival times in our two evaluated schedules were 1.5 years (docetaxel followed by AC) and 1.1 years (AC followed by docetaxel), thus reflecting the lack of direct relationship between response rate and median survival times for the regimens tested. The drug doses were identical to those in the present study, but each therapy was administered for four cycles rather than the three cycles here.
Preliminary information from a three-arm study evaluating different sequences of docetaxel and FEC (5-fluorouracil, epirubicin, cyclophosphamide) has recently become available [53] . This abstract reports data from 69 of 136 patients enrolled to receive docetaxel 10 mg/m 2 and FEC either alternating every other cycle × 8, or one schedule × 4 followed by the other one × 4. Absolute responses were between 64% and 88%, but 95% CIs were not provided. Further follow-up of these data should provide more insight into the relative value of docetaxel alone versus sequential or alternating treatment with an anthracycline-based regimen.
Given the wealth of higher response rate data for docetaxel as monotherapy and as part of a doxorubicin-based combination and sequential schedules, the low response rates in the present study were surprising. It is possible that patients did not receive a high enough dose of either docetaxel or AC for long enough to achieve even the expected response rates for these therapies. The incidence of dose reduction was high: at cycle 3, only 25% of patients on docetaxel and 54% on AC received >95% of the starting dose. The median number of cycles administered was higher in the Antoine et al. [52] study (11 cycles) than in the present study (seven cycles of docetaxel then AC; 9.5 cycles of AC then docetaxel).
The majority of the dose reductions in the present study were due to grade 4 neutropenia. This raises the question (albeit speculative) of whether increased dose intensity perhaps by prophylactic growth factor support, which was not permitted, could have been beneficial. The abstract by Antoine et al. [52] of sequential docetaxel then AC therapy did not include data regarding growth support criteria. However, in dose-finding studies of docetaxel-based schedules in metastatic breast cancer patients, prophylactic growth factor support allowed higher doses to be delivered safely [54, 55] .
The translational aspect of our trial also generated provocative data. Before this study, several reports have shown that holoreceptor and/or corresponding soluble receptor protein products of the c-erbB2 (HER2/neu) gene are altered in breast cancer patients [41-45, 49, 56-59] . Interestingly, ErbB2 is an orphan receptor that appears to function solely as a cofactor for signaling through either the ErbB1/EGF axis, or alternately through the heregulin axis via its association with either ErbB3 or ErbB4. One, therefore, might predict that serum levels of soluble ErbB receptors might be coordinately regulated. We have recently demonstrated that a soluble form of the EGFR, i.e. p110 sErbB1, is present in human serum [39] . In this study, we compared pre-and post-treatment sErbB1 and sErbB2 concentrations in advanced breast cancer patients. Our results demonstrate that there are no significant differences between sErbB1 concentrations in breast cancer patients previously untreated with systemic chemotherapy and those of healthy women. In addition, sErbB1 concentrations did not appear to change during the course of either treatment schedule. In contrast, the sErbB2 concentrations in breast cancer patients previously untreated with systemic chemotherapy were significantly higher than in healthy women, and serum sErbB2 concentrations tended to decrease over the course of treatment. A larger study in metastatic breast cancer patients will be needed to confirm these observations, and to determine whether these effects on sErbB2 concentrations can be used to predict and/or monitor clinical responsiveness to chemotherapy.
In conclusion, the sequential docetaxel/AC schedules as administered in the present study led to lower response rates than anticipated at the end of six cycles of treatment but led to median survival times to similar those of some other trials in metastatic breast cancer. Further studies to assess whether sErbB2 concentrations are useful predictors of responsiveness to chemotherapy are warranted.
